36 Healthcare Stocks Moving In Wednesday's After-Market Session

Gainers

Innovate, Inc. INNT stock surged 29.2% to $0.85 during Wednesday's after-market session.

Genprex, Inc. GNPX shares moved upwards by 14.8% to $2.17.

Alector, Inc. ALEC shares surged 11.2% to $25.50. The most recent rating by BTIG, on November 21, is at Buy, with a price target of $28.00.

Ritter Pharmaceuticals, Inc. RTTR stock moved upwards by 6.4% to $0.21.

Solid Biosciences, Inc. SLDB stock rose 5.9% to $3.95. The most recent rating by Nomura, on December 19, is at Buy, with a price target of $10.00.

Sierra Oncology, Inc. SRRA stock rose 5.8% to $0.37. The most recent rating by Oppenheimer, on December 06, is at Outperform, with a price target of $1.20.

Marinus Pharmaceuticals, Inc. MRNS stock rose 5.8% to $2.38. The most recent rating by H.C. Wainwright, on January 10, is at Buy, with a price target of $6.00.

Achieve Life Sciences, Inc. ACHV stock increased by 5.5% to $0.63.

Unum Therapeutics, Inc. UMRX stock rose 5.0% to $1.25. The most recent rating by Morgan Stanley, on November 27, is at Overweight, with a price target of $3.00.

Affimed, Inc. AFMD stock increased by 4.5% to $3.03.

Osmotica Pharmaceuticals, Inc. OSMT stock increased by 4.3% to $6.99.

Organovo Holdings, Inc. ONVO stock increased by 4.3% to $0.38.

Precipio, Inc. PRPO stock surged 4.3% to $2.20. The most recent rating by Maxim Group, on November 22, is at Buy, with a price target of $4.00.

Neurotrope, Inc. NTRP stock increased by 4.2% to $1.48.

InMode, Inc. INMD stock surged 4.1% to $48.05. The most recent rating by Roth Capital, on December 19, is at Buy, with a price target of $13.00.

Teligent, Inc. TLGT shares increased by 3.6% to $0.43.

MannKind, Inc. MNKD stock surged 3.5% to $1.75. According to the most recent rating by Oppenheimer, on December 24, the current rating is at Outperform.

Akerna, Inc. KERN shares increased by 3.5% to $8.82.

Nektar Therapeutics, Inc. NKTR stock surged 3.3% to $22.87. The most recent rating by JP Morgan, on November 13, is at Neutral, with a price target of $28.00.

Oncolytics Biotech, Inc. ONCY stock increased by 3.3% to $3.46.

Lexicon Pharmaceuticals, Inc. LXRX stock increased by 3.2% to $3.89. According to the most recent rating by Gabelli & Co., on December 11, the current rating is at Hold.

Baudax Bio, Inc. BXRX stock moved upwards by 3.2% to $8.80.

HEXO, Inc. HEXO stock rose 3.1% to $1.48.

Jaguar Health, Inc. JAGX shares increased by 3.0% to $0.85. The most recent rating by H.C. Wainwright, on November 18, is at Buy, with a price target of $3.00.

 

Losers

Tetraphase Pharmaceutical, Inc. TTPH stock fell 23.2% to $2.95 during Wednesday's after-market session. The most recent rating by Gabelli & Co., on October 31, is at Buy, with a price target of $5.00.

Karuna Therapeutics, Inc. KRTX shares plummeted 12.1% to $101.35. The most recent rating by Wells Fargo, on January 22, is at Overweight, with a price target of $137.00.

Dare Bioscience, Inc. DARE shares declined 11.8% to $1.50.

Trillium Therapeutics, Inc. TRIL shares fell 10.6% to $2.92.

Option Care Health, Inc. BIOS shares declined 8.0% to $4.01.

Concert Pharmaceuticals, Inc. CNCE stock fell 5.3% to $12.40.

Midatech Pharma, Inc. MTP stock decreased by 5.1% to $0.84.

Axonics Modulation Tech, Inc. AXNX shares plummeted 4.8% to $30.02. The most recent rating by SunTrust Robinson Humphrey, on January 08, is at Buy, with a price target of $38.00.

Biocept, Inc. BIOC stock decreased by 3.5% to $0.33.

vTv Therapeutics, Inc. VTVT shares declined 3.5% to $2.50.

Xenon Pharmaceuticals, Inc. XENE stock plummeted 3.5% to $16.25. According to the most recent rating by William Blair, on January 08, the current rating is at Outperform.

Titan Pharmaceuticals, Inc. TTNP shares decreased by 3.3% to $0.32.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: After-Hours CenterMarketsMoversTrading IdeasHealthcare Stocks After-Market MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!